CHICAGO--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, today announced that it presented data during the American Society of Clinical Oncology’s 2014 Annual Meeting which demonstrates that the oncology biomarker miR-31-3p is predictive of cetuximab effects in wild-type (WT) KRAS metastatic colorectal cancer (mCRC) patients. The data presented was based on a post-hoc analysis of patients enrolled in the New EPOC phase III trial who were randomized to receive chemotherapy alone or chemotherapy plus cetuximab before and after resection of colorectal liver metastasis.
Help employers find you! Check out all the jobs and post your resume.
